U.S. Markets open in 6 hrs 6 mins

Miragen Therapeutics (MGEN) Upgraded to Buy at Zacks Investment Research

The Cerbat Gem

Zacks Investment Research upgraded shares of Miragen Therapeutics (NASDAQ:MGEN) from a hold rating to a buy rating in a report released on Tuesday. They currently have $10.00 price objective on the medical research company’s stock. According to Zacks, “Miragen Therapeutics, Inc. is a biopharmaceutical company. It develops microRNA biology, oligonucleotide chemistry, drugs and therapies for cancer, pathologic fibrosis, neuro-inflammatory and cardiovascular diseases. Miragen Therapeutics, Inc., formerly known as Signal Genetics, is headquartered in Boulder, Colorado. “ A number of other analysts have also commented on MGEN. Chardan Capital reissued a buy rating and issued a $29.00 price objective